EN 101

Drug Profile

EN 101

Alternative Names: EN-101; Monarsen

Latest Information Update: 23 Apr 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hebrew University of Jerusalem
  • Developer Amarin Corporation
  • Class Oligodeoxyribonucleotides
  • Mechanism of Action Acetylcholinesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myasthenia gravis
  • Available For Licensing Yes - Amyotrophic lateral sclerosis; Inflammatory bowel diseases; Myasthenia gravis

Highest Development Phases

  • Discontinued Amyotrophic lateral sclerosis; Inflammatory bowel diseases; Myasthenia gravis

Most Recent Events

  • 08 Nov 2010 EN 101 is available for worldwide licensing in myasthenia gravis, inflammatory bowel disease and amyotrophic lateral sclerosis as of 06 Oct 2008. http://www.amarincorp.com
  • 18 Jun 2009 Suspended - Preclinical for Amyotrophic lateral sclerosis (PO)
  • 18 Jun 2009 Suspended - Preclinical for Inflammatory bowel disease (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top